8-K: Carisma Therapeutics Appoints Interim VP of Finance, Enters Service Agreement with Danforth Global

Carisma Therapeutics has appointed Natalie McAndrew as interim Vice President of Finance, effective January 1, 2025, while also engaging Danforth Global for finance and accounting services.

Summary

• Carisma Therapeutics has entered into a master services agreement with Danforth Global, Inc. and Danforth Advisors, LLC, effective January 1, 2025.
• Danforth will provide finance and accounting services to Carisma, with Natalie McAndrew, a Senior Director at Danforth, serving as the primary service provider.
• Carisma will pay Danforth an hourly rate for services and reimburse expenses.
• The agreement can be terminated with 30 days' notice for cause or 60 days' notice without cause.
• The Board of Directors has appointed Ms. McAndrew as the interim Vice President of Finance, also effective January 1, 2025.
• In this role, Ms. McAndrew will serve as the company's principal financial officer and principal accounting officer.
• Ms. McAndrew has extensive experience in finance and accounting, including previous roles at Danforth, Apertura Gene Therapy, Baudax Bio, and Spark Therapeutics.
• The initial budget for the engagement is $33,600 per month, and Danforth will notify Carisma if this budget is likely to be exceeded.
• Danforth's hourly rates can increase by up to 6% annually, starting January 1, 2026.

Sentiment

Score: 7

Explanation: The document reflects a positive step for Carisma in securing financial expertise, but there are potential cost increases and termination risks. The sentiment is moderately positive.

Positives

• Carisma has secured experienced financial leadership with the appointment of Natalie McAndrew as interim VP of Finance.
• The engagement of Danforth provides access to a team of finance and accounting professionals.
• The agreement includes a defined budget of $33,600 per month, providing cost control.
• The agreement allows for flexibility with termination clauses.
• The agreement includes provisions for D&O insurance coverage for Danforth staff serving as directors or officers of the Company.

Negatives

• The agreement allows for Danforth to increase hourly rates by up to 6% annually starting in 2026, which could increase costs.
• The agreement includes a clause that allows Danforth to pause services if fees are unpaid after 60 days.
• The agreement includes a clause that allows Danforth to terminate the agreement if the D&O insurance is not acceptable.

Risks

• Potential for increased costs due to annual rate increases by Danforth.
• Risk of service disruption if payments are delayed beyond 60 days.
• The agreement can be terminated by either party with 30 or 60 days' notice, which could lead to instability.
• The company is reliant on Danforth for key financial functions, which could pose a risk if the relationship is terminated.
• The company may need to find a permanent VP of Finance in the future.

Future Outlook

The agreement is set to continue until terminated by either party, with potential for annual rate increases from Danforth. Carisma will need to monitor the budget and performance of Danforth's services.

Management Comments

• The document does not contain any direct quotes from management, but the agreement and appointment indicate a strategic move to strengthen the company's financial operations.

Industry Context

The engagement of an outsourced finance and accounting firm is a common practice for biopharmaceutical companies, especially those in early stages or experiencing rapid growth. This allows them to access specialized expertise without the overhead of hiring full-time staff.

Comparison to Industry Standards

• Many biotech companies use outsourced financial services, similar to Carisma's engagement with Danforth.
• The use of interim CFOs or VPs of Finance is also common during transitions or periods of rapid growth.
• The hourly rates and annual increase clauses are typical in consulting agreements within the life sciences industry.
• The D&O insurance requirements are standard for companies engaging external financial professionals in leadership roles.
• Companies like Baudax Bio, where Ms. McAndrew previously served as interim CFO, also utilize similar outsourced financial arrangements.

Management Changes

Stakeholder Impact

• Shareholders will likely view the appointment of an experienced financial professional positively.
• Employees may experience changes in financial processes and reporting.
• Customers and suppliers may not be directly impacted by this announcement.
• Creditors may gain confidence in the company's financial management.

Next Steps

• Carisma will integrate Danforth's services into its financial operations.
• Carisma will monitor the budget and performance of Danforth's services.
• Carisma will ensure compliance with the terms of the service agreement.
• Carisma will need to consider a permanent VP of Finance in the future.

Key Dates

Keywords

finance, accounting, interim VP of Finance, master services agreement, Danforth Global, Natalie McAndrew, financial officer, biopharmaceutical, outsourced services, D&O insurance